NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) – Analysts at B. Riley reduced their FY2023 EPS estimates for shares of NGM Biopharmaceuticals in a research note issued to investors on Wednesday, March 29th. B. Riley analyst M. Mamtani now expects that the company will earn ($1.79) per share for the year, down from their previous […]
NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its price target decreased by B. Riley from $8.00 to $7.00 in a research note issued to investors on Thursday, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, Q2 […]